2. 疾患領域
  3. Cancer
  4. Breast Cancer
  5. Luminal Breast Cancer

Luminal Breast Cancer

Luminal A breast cancer is a subtype of breast cancer accounting for 40–55% of cases, defined by estrogen receptor (ER) and/or progesterone receptor (PR) positivity, HER2 negativity, and a low Ki-67 proliferation index (<14%), typically presenting as well-differentiated tumors. It is associated with a favorable prognosis and responsiveness to endocrine therapy. Key molecular features include expression of ER/PR, absence of HER2 amplification, and involvement of pathways such as chromatin regulation and acetylation, with HJURP as a related gene. Therapeutic agents like Fulvestrant and Palbociclib are used in treatment. This subtype is linked to tissues including breast and myeloid, and phenotypic traits include increased shRNA abundance and enhanced Salmonella-containing vacuole maturation. Luminal B breast cancer is a hormone receptor-positive (HR+) and HER2-positive breast cancer subtype with a more aggressive phenotype and poorer prognosis compared to luminal A breast cancer. It is characterized by overlapping expression of estrogen and progesterone receptors, increased proliferation, and potential benefit from additional systemic and local therapies. The ERBB2 gene is a key driver, and the condition is linked to pathways such as CREB signaling and ion channel transport. Affected tissues primarily include the breast, and it has associations with familial episodic pain syndrome and mucolipidosis IV.

Luminal Breast Cancer (41):

製品番号 製品名 CAS 番号 純度 構造式
  • HY-13757
    Tamoxifen Citrate

    タモキシフェンクエン酸塩

    		54965-24-1 99.88%
    Tamoxifen Citrate (ICI 46474) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells.Tamoxifen Citrate is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen Citrate also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 μM and 1.8 μM, respectively. Tamoxifen Citrate activates autophagy and induces apoptosis. Tamoxifen Citrate can also be used to induce gene knockout in CreER transgenic mice.
    Tamoxifen Citrate
  • HY-13757A
    Tamoxifen

    タモキシフェン

    		10540-29-1 99.96%
    Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells. Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 μM and 1.8 μM, respectively. Tamoxifen activates autophagy and induces apoptosis. Tamoxifen can also be dissolved in corn oil (HY-Y1888) for use in inducing gene knockout in CreER transgenic mice. Tamoxifen has better solubility in corn oil compared to Tamoxifen Citrate (HY-13757).
    Tamoxifen
  • HY-50767
    Palbociclib

    パルボシクリブ

    		571190-30-2 99.94%
    Palbociclib (PD 0332991) is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma.
    Palbociclib
  • HY-P9907
    Trastuzumab 180288-69-1 99.80%
    Trastuzumab is a humanized IgG1 monoclonal antibody that selectively binds to HER2 with high affinity. Trastuzumab can be used for the research of HER2-positive metastatic breast cancer and gastric cancer. (Note: The product specifications below only indicate the effective content of Trastuzumab. The component ratio of this product is Trastuzumab : excipients = 1:0.6-1:0.9.)
    Trastuzumab
  • HY-13636
    Fulvestrant

    フルベストラント

    		129453-61-8 99.98%
    Fulvestrant (ICI 182780) is a pure antiestrogen and a potent estrogen receptor (ER) antagonist with an IC50 of 9.4 nM. Fulvestrant is also a GPR30 agonist. Fulvestrant effectively inhibits the growth of ER-positive MCF-7 cells with an IC50 of 0.29 nM. Fulvestrant also induces autophagy and has antitumor efficacy.
    Fulvestrant
  • HY-13631E
    Deruxtecan 1599440-13-7 99.94%
    Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing Trastuzumab deruxtecan (HY-138298A) and Patritumab deruxtecan (HY-P99813).
    Deruxtecan
  • HY-182468
    OP-3136 3056105-63-3 99.90%
    OP-3136 is a selective KAT6 inhibitor. OP-3136 reduces the proliferative capacity of cancer cells and inhibits cell growth in ER+ breast cancer cell models with overexpressed KAT6. When combined with ER antagonists/degraders or CDK4/6 inhibitors, OP-3136 exhibits synergistic anti-tumor activity in mouse xenograft models. OP-3136 can be used in studies related to HR+/HER2- breast cancer.
    OP-3136
  • HY-183285
    PI3Kα-IN-32 3057582-20-1
    PI3Kα-IN-32 (Compound 11f) is a selective, orally active PI3Kα inhibitor, with an IC50 of 26.3 nM against PI3KαH1047R. PI3Kα-IN-32 inhibits AKT phosphorylation. PI3Kα-IN-32 exhibits anticancer activity against breast cancer. PI3Kα-IN-32 can be used in the research of HR+/HER2- breast cancer.
    PI3Kα-IN-32
  • HY-124627
    THIQ 40 1799430-91-3
    THIQ-40 is a tetrahydroisoquinoline-based, orally active, and selective estrogen receptor ERα degrader (SERD) (IC50=17 nM), with antitumor efficacy. THIQ-40 possesses functional ERα antagonistic activity, promotes ERα degradation and forms stable ERαLBD complexes. THIQ-40 shows the characteristic of rapid racemization in multi-species plasma. THIQ-40 can be widely applied to studies on the relevant mechanisms and drug development of ERα-positive breast cancer.
    THIQ 40
  • HY-10218
    Everolimus

    エベロリムス

    		159351-69-6 99.85%
    Everolimus (RAD001) is a Rapamycin (HY-10219) derivative and a potent, selective, orally active, blood-brain barrier-permeable mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities.
    Everolimus
  • HY-16297A
    Abemaciclib 1231929-97-7 99.97%
    Abemaciclib (LY2835219) is a selective and BBB-permeable CDK4/6 inhibitor with IC50 values of 2 nM and 10 nM for CDK4 and CDK6, respectively.
    Abemaciclib
  • HY-15777
    Ribociclib 1211441-98-3 99.94%
    RRibociclib (LEE011) is an ATP-competitive and orally active CDK4/6 inhibitor that crosses the blood-brain barrier with IC50 values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex.
    Ribociclib
  • HY-P9907A
    Trastuzumab (anti-HER2) 180288-69-1 99.838%
    Trastuzumab (anti-HER2) is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab (anti-HER2) has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.
    Trastuzumab (anti-HER2)
  • HY-P99380
    Zanidatamab 2169946-15-8 98.56%
    Zanidatamab (ZW25) is a humanised, bispecific monoclonal antibody targeting 2 distinct HER2 epitopes (ECD2 and ECD4). Zanidatamab has anti-tumour activity.
    Zanidatamab
  • HY-A0065
    Palbociclib isethionate

    Palbociclib (isethionate)

    		827022-33-3 99.98%
    Palbociclib (PD 0332991) isethionate is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib isethionate has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma.
    Palbociclib isethionate
  • HY-13757AR
    Tamoxifen (Standard) 10540-29-1
    Tamoxifen (Standard) is the analytical standard of Tamoxifen (HY-13757A). This product is intended for research and analytical applications. Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells. Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 μM and 1.8 μM, respectively. Tamoxifen activates autophagy and induces apoptosis. Tamoxifen also can induce gene knockout of CreER(T2) transgenic mouse.
    Tamoxifen (Standard)
  • HY-13673A
    Goserelin acetate

    酢酸ゴセレリン

    		145781-92-6 99.93%
    Goserelin acetate (ICI-118630 acetate), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin acetate can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer.
    Goserelin acetate
  • HY-15777B
    Ribociclib succinate 1374639-75-4 99.93%
    RRibociclib (LEE011) succinate is an ATP-competitive and orally active CDK4/6 inhibitor that crosses the blood-brain barrier with IC50 values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex.
    Ribociclib succinate
  • HY-15777A
    Ribociclib hydrochloride 1211443-80-9 99.95%
    RRibociclib (LEE011) hydrochloride is an ATP-competitive and orally active CDK4/6 inhibitor that crosses the blood-brain barrier with IC50 values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex.
    Ribociclib hydrochloride
  • HY-108730A
    Avelumab (anti-PD-L1) 1537032-82-8
    Avelumab (anti-PD-L1) a fully human IgG1 anti-PD-L1 monoclonal antibody (mAb) with potential antibody-dependent cell-mediated cytotoxicity (ADCC). Avelumab (anti-PD-L1) enhances ADCC on several cancer cell lines expressing PD-L1. Avelumab (anti-PD-L1) can be used for the study of chordoma.
    Avelumab (anti-PD-L1)